# Molecular Dynamics and Artificial Intelligence Based Tools to Innovate Covalent and Noncovalent Drug Design

> **NIH NIH R44** · COMPUTCHEM LLC · 2021 · $702,792

## Abstract

Abstract
Cancer and infectious diseases are threatening modern human kind. To combat the challenge, targeted cova-
lent inhibition and targeted protein degradation are emerging as the new frontiers in drug discovery. This SBIR
project seeks to meet two unmet needs in the emerging covalent as well as traditional reversible drug discovery
programs by developing two commercial solutions based on cutting-edge research in molecular simulations and
data science. In the Phase I period, ComputChem LLC has developed a local/cloud software application iTitrate
that can offer accurate and reliable predictions of protein pKa values and nucleophilic cysteine and lysine. As the
ﬁrst of its kind, iTitrate is based on a unique and extensively validated constant pH molecular dynamics approach
and a very accurate and efﬁcient generalized Born implicit-solvent model. In Phase I, ComputChem also devel-
oped a prototype of a novel small-molecule pKa prediction tool based on artiﬁcial intelligence. Building on the
Phase I progress, the objective of the Phase II project is to signiﬁcantly accelerate, enhance, and demonstrate
the capabilities of iTitrate and improve the accuracy of iKa. iTitrate can be applied to expedite efforts in a vari-
ety of covalent drug discovery programs, including targeted covalent inhibitor design; kinome or proteome wide
scanning for covalently targetable sites; protein-protein interaction inhibition; and proteolysis targeting chimera
design. iTitrate can be further developed and integrated with iKa to offer a novel solution for accurate protonation
state assignment and pH-dependent modeling of protein-ligand complexes, which would add signiﬁcant value to
computer-aided lead optimization and other in silico drug design tasks.

## Key facts

- **NIH application ID:** 10323917
- **Project number:** 2R44GM134756-02A1
- **Recipient organization:** COMPUTCHEM LLC
- **Principal Investigator:** Julie Anne Harris
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $702,792
- **Award type:** 2
- **Project period:** 2019-09-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10323917

## Citation

> US National Institutes of Health, RePORTER application 10323917, Molecular Dynamics and Artificial Intelligence Based Tools to Innovate Covalent and Noncovalent Drug Design (2R44GM134756-02A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10323917. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
